The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients
NCT04902690
·
clinicaltrials.gov ↗
UNKNOWN
Status
21
Enrollment
OTHER
Sponsor class
Conditions
Multiple Sclerosis Relapse
Sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation